$SFBC

SFBC (SFBC) CEO’s charitable trust sells 900 shares in 10b5-1 trade

Sound Financial Bancorp, Inc. (SFBC) President and CEO Laura Lee Stewart's charitable trust sold 900 shares of common stock at $44.13 per share on March 31, 2026, as part of a pre-set Rule 10b5-1(c) trading plan. After the transaction, the trust holds 9,900 shares, while Stewart directly owns 49,602 shares and has indirect holdings through an ESOP and 401(k), along with various stock options. The sale was executed by the trustee of the Stewart Charitable Remainder Trust, established for estate planning purposes.

Original reporting
Published Apr 1, 2026, 4:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SFBC
Neutral
medium confidence
Mentioned
$SFBC
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$SFBCNeutralLow
01

Why it matters

While insider sales can sometimes signal lack of confidence, in this case, the pre-arranged plan suggests it may not reflect negative sentiment towards SFBC.

02

Market read

The transaction has limited market relevance, primarily affecting perceptions of insider confidence rather than company fundamentals.

03

What to watch

The company's fundamentals and recent financial results should be considered before adjusting positions.

Relevance 6/10Timing: short-term

Background

The sale was executed by the trustee of the Stewart Charitable Remainder Trust, established for estate planning, indicating a planned and non-urgent transaction.

Company-level read

Ticker impact

$SFBCNeutralMedium confidence
Context

The news involves insider trading activity of SFBC's CEO's charitable trust.

Expected impact

Minimal short-term impact; potential slight bearish bias due to insider selling, but limited due to planned nature.

Evidence & confidence

The sale was pre-arranged, reducing the likelihood of negative surprise. The low relevance score (1.0) indicates limited broader market impact.

Market effects

Limited sector impact; financial services sector may see minor cautious sentiment.

Negligible impact on regional markets.

Minimal; specific to SFBC and its immediate stakeholders.

Counterpoint

The insider sale may be part of routine estate planning and not indicative of company performance.

Key entities

  • Laura Lee Stewart

    President and CEO of Sound Financial Bancorp, Inc.

  • Sound Financial Bancorp, Inc.

    Financial services company traded as SFBC.

Related articles

$SFBCMed

Sound Financial Bancorp, Inc. Q3 2026 Results

Sound Financial Bancorp, Inc. (SFBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sound Financial Bancorp, Inc. Q3 2026 Results Seattle, WA, October 27, 2026 — Sound Financial Bancorp, Inc. (the "Company") (Nasdaq: SFBC), the holding company for Sound Community Bank (the "Bank"), today reported net income of $2.3 million for the quarter ended September 30, 202

$SFBCMed

Sound Financial Bancorp, Inc. Q2 2026 Results

Sound Financial Bancorp, Inc. (SFBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a06302026earningsrelease-e.htm EX-99.1 Document Sound Financial Bancorp, Inc. Q2 2026 Results Seattle, WA, July 28, 2026 — Sound Financial Bancorp, Inc. (the "Company") (Nasdaq: SFBC), the holding company for Sound Community Bank (the "Bank"), today reported net income

$ACRSMedAI 8/10

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics (ACRS) reported positive early results for ATI-052 in Phase 1b trials for eczema and asthma. ATI-052 showed a 43% placebo-adjusted improvement in itch scores at week eight and a 59% reduction in FeNO in asthma patients. No serious adverse events were reported. Aclaris plans to start a Phase 2b/3 program for eosinophilic esophagitis early next year and secured $50 million in financing.